Please wait while the formulary information is being retrieved.
Drug overview for DAYLOGIC MINOXIDIL (minoxidil):
Generic name: minoxidil (min-OX-id-ill)
Drug class:
Therapeutic class: Dermatological
Minoxidil is a piperidinopyrimidine-derivative vasodilator that possesses hair growth stimulant properties.
No enhanced Uses information available for this drug.
Generic name: minoxidil (min-OX-id-ill)
Drug class:
Therapeutic class: Dermatological
Minoxidil is a piperidinopyrimidine-derivative vasodilator that possesses hair growth stimulant properties.
No enhanced Uses information available for this drug.
DRUG IMAGES
No Image Available
The following indications for DAYLOGIC MINOXIDIL (minoxidil) have been approved by the FDA:
Indications:
Alopecia
Professional Synonyms:
Acomia
Calvities
Pelade
Indications:
Alopecia
Professional Synonyms:
Acomia
Calvities
Pelade
The following dosing information is available for DAYLOGIC MINOXIDIL (minoxidil):
When the dropper applicator is used as directed, the applicator delivers 1 mL of minoxidil topical solution (20 or 50 mg of minoxidil in the 2 or 5% solution, respectively). When the metered-spray or extender-spray applicator is used, delivery of a 1-mL dose requires pumping the spray attachment 6 times (i.e., with approximately 3.3 or 8.3 mg of drug per metered spray with the 2 or 5% solution, respectively). When used as directed, each bottle of minoxidil topical solution should last 25-30 days provided substantial amounts of solution are not lost during applicator changes.
Minoxidil solution is applied topically to the scalp. Twice-daily application appears to be necessary for optimum results. Individuals receiving topical minoxidil therapy should be carefully instructed regarding proper use of the solution.
To obtain optimum results, these individuals should be given a copy of the instructions provided by the manufacturers. Topical minoxidil solution is applied to the total affected areas of the scalp using one of the applicators provided by the manufacturers (i.e., metered-spray applicator, extender spray applicator, dropper applicator). The manufacturers' patient information should be consulted for specific methods of application.
Individuals being treated for androgenetic alopecia should be advised that because of the risk of adverse systemic effects, the topical preparation is intended for application to the scalp only and should not be applied to other areas of the body. Prior to application of minoxidil topical solution, the hair and scalp should be dry. Individuals applying minoxidil topical solution with their fingertips should be instructed to wash their hands thoroughly afterward. When the metered-spray or extender-spray applicator is used, inhalation of the spray mist should be avoided.
To obtain optimum results, these individuals should be given a copy of the instructions provided by the manufacturers. Topical minoxidil solution is applied to the total affected areas of the scalp using one of the applicators provided by the manufacturers (i.e., metered-spray applicator, extender spray applicator, dropper applicator). The manufacturers' patient information should be consulted for specific methods of application.
Individuals being treated for androgenetic alopecia should be advised that because of the risk of adverse systemic effects, the topical preparation is intended for application to the scalp only and should not be applied to other areas of the body. Prior to application of minoxidil topical solution, the hair and scalp should be dry. Individuals applying minoxidil topical solution with their fingertips should be instructed to wash their hands thoroughly afterward. When the metered-spray or extender-spray applicator is used, inhalation of the spray mist should be avoided.
No dosing information available.
No generic dosing information available.
The following drug interaction information is available for DAYLOGIC MINOXIDIL (minoxidil):
There are 0 contraindications.
There are 0 severe interactions.
There are 0 moderate interactions.
The following contraindication information is available for DAYLOGIC MINOXIDIL (minoxidil):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 1 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| Dermatosis of the scalp |
There are 0 severe contraindications.
There are 0 moderate contraindications.
The following adverse reaction information is available for DAYLOGIC MINOXIDIL (minoxidil):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 21 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. |
Dermatitis due to topical drug Pruritus of skin Skin rash Urticaria |
| Rare/Very Rare |
|---|
|
Abnormal sexual function Alopecia Angioedema Body fluid retention Cardiac arrhythmia Chest pain Dizziness Eczema Edema Folliculitis Head sensation disturbance Headache disorder Hypotension Neuralgia Reduced visual acuity Tachycardia Visual changes |
There are 3 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. |
Dry skin Erythema |
| Rare/Very Rare |
|---|
|
Vasodilation of blood vessels |
The following precautions are available for DAYLOGIC MINOXIDIL (minoxidil):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
Although there are no adequate and controlled studies to date in humans receiving oral or topical minoxidil, orally administered minoxidil has been associated with evidence of increased fetal resorption in rabbits, but not rats, when given at dosages 5 times the maximum recommended human oral antihypertensive dosage. There was no evidence of teratogenic effects of orally administered minoxidil in rats or rabbits. There was no evidence of teratogenic effects in rats receiving subcutaneous minoxidil dosages of 80 mg/kg daily (about 2000 times the maximal systemic human exposure achieved with daily administration of topical minoxidil); however, maternal toxicity was observed with this dosage.
Evidence of developmental toxicity was observed in rats receiving subcutaneous dosages exceeding 80 mg/kg daily. For additional information on the potential risks of oral minoxidil therapy during pregnancy, see Cautions: Pregnancy, Fertility, and Lactation, in Minoxidil 24:08.20. The effects of the drug on labor and delivery are not known.
Evidence of developmental toxicity was observed in rats receiving subcutaneous dosages exceeding 80 mg/kg daily. For additional information on the potential risks of oral minoxidil therapy during pregnancy, see Cautions: Pregnancy, Fertility, and Lactation, in Minoxidil 24:08.20. The effects of the drug on labor and delivery are not known.
Minoxidil is distributed into milk after oral administration. Because of the potential for serious adverse effects in nursing infants if topically applied drug were absorbed percutaneously and distributed into breast milk, the manufacturer recommends that minoxidil topical solution not be administered to nursing women.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for DAYLOGIC MINOXIDIL (minoxidil):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for DAYLOGIC MINOXIDIL (minoxidil)'s list of indications:
| Alopecia | |
| A51.32 | Syphilitic alopecia |
| L63 | Alopecia areata |
| L63.0 | Alopecia (capitis) totalis |
| L63.1 | Alopecia universalis |
| L63.2 | Ophiasis |
| L63.8 | Other alopecia areata |
| L63.9 | Alopecia areata, unspecified |
| L64 | Androgenic alopecia |
| L64.0 | Drug-induced androgenic alopecia |
| L64.8 | Other androgenic alopecia |
| L64.9 | Androgenic alopecia, unspecified |
| L65 | Other nonscarring hair loss |
| L65.0 | Telogen effluvium |
| L65.2 | Alopecia mucinosa |
| L65.8 | Other specified nonscarring hair loss |
| L65.9 | Nonscarring hair loss, unspecified |
| L66 | Cicatricial alopecia [scarring hair loss] |
| L66.0 | Pseudopelade |
| L66.1 | Lichen planopilaris |
| L66.10 | Lichen planopilaris, unspecified |
| L66.11 | Classic lichen planopilaris |
| L66.12 | Frontal fibrosing alopecia |
| L66.19 | Other lichen planopilaris |
| L66.2 | Folliculitis decalvans |
| L66.3 | Perifolliculitis capitis abscedens |
| L66.4 | Folliculitis ulerythematosa reticulata |
| L66.8 | Other cicatricial alopecia |
| L66.81 | Central centrifugal cicatricial alopecia |
| L66.89 | Other cicatricial alopecia |
| L66.9 | Cicatricial alopecia, unspecified |
Formulary Reference Tool